What is MetLife's latest dividend and current dividend yield?

What were the key takeaways from MetLife's earnings call?

What were the key takeaways from MetLife’s earnings call?

What guidance did MetLife's management provide for the next earnings period?

Did MetLife beat or miss consensus estimates last quarter?

What is the market's earnings forecast for MetLife next quarter?

What does MetLife do and what are its main business segments?

What factors drove the changes in MetLife's revenue and profit?

- **10% EPS Growth Achieved**: 2025 adjusted EPS of $8.89, with 10% growth excluding notable items.
- **Efficiency Drive**: Direct expense ratio at 11.7%, 100bps ahead of 5-year target, enabled by AI adoption.
- **MIM Expansion**: $742 billion AUM post-PineBridge, 2026 MIM earnings $240-$280 million.
- **Capital Strength**: $4.9 billion free cash flow in 2025, on track for $25 billion 5-year target.
- **Risks**: Higher MIM-related expenses (50bps), but offset by strategic growth.

**【CEO Summary Section】**
- MetLife achieved 10% adjusted EPS growth in 2025, excluding notable items, driven by strong volume growth and capital management.
- Strategic initiatives include AI adoption, reducing direct expense ratio to 11.7% (target 11.3% by 2029), and $4.9 billion free cash flow toward a 5-year $25 billion target.
- Key business highlights: Group Benefits added $600 million in new adjusted premiums, PRT sales reached $14 billion (highest annual total), and MIM AUM grew to $742 billion post-PineBridge acquisition.
- Capital deployment: $4 billion for organic growth, $4.4 billion returned to shareholders via buybacks and dividends.

**【CFO Financial Commentary】**
- 2025 adjusted EPS: $8.89 (10% growth), adjusted ROE: 16% (within 15%-17% target).
- Direct expense ratio improved to 11.7%, beating 12.1% target, with AI-driven efficiency.
- 2026 outlook: Double-digit EPS growth, ROE 15%-17%, MIM adjusted earnings $240-$280 million.
- Risks: Higher expense ratio from MIM (50bps), but offset by long-term growth opportunities.

**【Q&A Key Highlights】**
- **Group Benefits Renewal Season**: Dental persistency improved, disability claims higher severity but within pricing expectations.
- **Japan Market Dynamics**: Sales growth 18% (FX-denominated products), but Q4 surrenders elevated due to yen depreciation.
- **MIM Expansion**: PineBridge integration on track, 2026 revenue growth 30%, targeting 32% operating margin by 2028.
- **AI Impact**: No material workforce reduction; focus on process reengineering and customer experience enhancement.

MetLife, Inc. (MET) Q4 2025 Earnings Call Transcript

- **Adjusted Earnings Beat**: $1.6B (22% YoY) driven by $483M variable investment income and 15% RIS growth.
- **New Frontier Success**: Japan sales +31%, Latin America PFOs +11%, and Chariot Re $10B transaction.
- **Expense Efficiency**: 11.6% direct expense ratio vs. 12.1% target, fueled by AI and $3B+ tech investment.
- **PRT Record Quarter**: $12B wins with 19% IRR, supporting 15%+ RIS growth.
- **Capital Strength**: $4.9B liquidity, $17.1B U.S. capital, and Japan solvency ratio ~740%.

**【CEO Summary Section】**
- MetLife reported adjusted earnings of $1.6 billion (up 22% per share year-over-year) driven by variable investment income ($483M vs. $425M outlook) and strong growth in Group Benefits, RIS, and Asia.
- New Frontier strategy highlights include: Japan sales surge (+31% YoY), Latin America PFOs up 11%, and Chariot Re launch with $10B reinsurance transaction.
- Direct expense ratio improved to 11.6%, below 12.1% target, supported by AI-driven efficiency gains.

**【CFO Financial Commentary】**
- Notable items: $18M net increase from Mexico tax adjustment (-$71M charge) and annual actuarial review (+$89M).
- Segment growth: RIS (+15%), Asia (+36%), Latin America (+2%), driven by VII returns (3% Q3) and liability origination.
- Free cash flow generation: $875M returned to shareholders (Q3), including $500M buybacks and $375M dividends.
- Capital position: $4.9B cash/liquid assets, $17.1B U.S. statutory capital, and Japan solvency ratio ~740%.

**【Q&A Key Highlights】**
- **Asia Sales Strength**: Japan sales +31% YoY (new FX Life product), Korea/China bancassurance growth, and 2025 full-year guidance exceed.
- **Expense Discipline**: 11.6% direct expense ratio; 2025 target of 12.1% achievable via tech (AI platform MetIQ) and $3B+ 5-year tech investment.
- **PRT Momentum**: $12B Q4 wins (record quarter), focusing on jumbo deals with 19% IRR and 5-year payback via VNB metrics.
- **Credit Management**: 95% corporate bonds investment-grade; disciplined underwriting in private credit with no ratings inflation concerns.
- **Mexico Tax Impact**: 2025 charge $71M (Q3) + $20-25M Q4, 2026 impact $50-60M, with 2027+ normalization.


MetLife, Inc. (MET) Q3 2025 Earnings Call Transcript

- **Adjusted Earnings Resilience**: $1.4B Q2 earnings despite lower VII and underwriting pressures, with strong free cash flow ($900M shareholder returns). 
- **Sales Momentum**: 9% YoY growth in Asia (Japan +29%, Korea +36%) and Latin America ($233M adjusted earnings, +15% CC). 
- **Expense Efficiency**: Direct expense ratio at 11.7% vs. 12.1% target, reflecting disciplined cost management. 
- **Strategic Deals**: $10B Chariot Re launch and PineBridge acquisition on track, positioning for lower-risk growth. 
- **AI Growth Driver**: GenAI adoption improving claims processing and customer experience across regions.

**【CEO Summary Section】**
- MetLife reported adjusted earnings of $1.4 billion ($2.02 per share) for Q2 2025, reflecting less favorable underwriting and investment margins. 
- Group Benefits adjusted earnings were $400 million, down 25% YoY due to elevated claims in non-medical health and life products. 
- Asia sales rose 9% YoY (29% in Japan, 36% in Korea) on new product launches, while Latin America achieved $233 million in adjusted earnings, up 15% on a constant currency basis. 
- Strategic transactions included the $10 billion Chariot Re launch and progress on the PineBridge acquisition. 
- Free cash flow enabled $900 million in shareholder returns (dividends + buybacks) in Q2.

**【CFO Financial Commentary】**
- GAAP net income was $1.4 billion, with adjusted EPS of $2.02 (-11% YoY). 
- Direct expense ratio improved to 11.7% (vs. 12.1% target), driven by cost control. 
- Variable investment income (VII) was $195 million, below guidance but within the $175-225 million range. 
- Cash and liquid assets at holding companies were $5.2 billion, above the $3-4 billion target buffer. 
- U.S. statutory capital was $17.1 billion, down 3% YoY due to derivative losses and dividends.

**【Q&A Highlights】**
- **Non-Medical Health Claims**: Elevated disability claims in Q2 were one-off events; expect 200bps improvement in Q3/Q4. 
- **Asia Earnings**: Lower VII returns and yen strengthening impacted margins, but sales growth (9% YoY) and AUM expansion (6% YoY) offset. 
- **Chariot Re Growth**: Initial $10 billion transaction with MetLife-originated liabilities; expect more deals in 2025. 
- **AI Implementation**: GenAI adoption in claims, programming, and customer experience driving efficiency and growth. 
- **LTC Transactions**: Actively exploring risk transfer opportunities, but no immediate block sales planned.

MetLife, Inc. (MET) Q2 2025 Earnings Call Transcript

- **Resilient Earnings Growth**: Q1 adjusted EPS of $1.96 (+7% YoY) despite macro volatility, driven by Group Benefits underwriting and RIS inflows. 
- **Strategic Risk Reduction**: $10B VA reinsurance deal reduces tail risk by 40%, unlocking $250M capital value. 
- **Capital Efficiency**: 12% expense ratio, $4.5B cash buffer, and $3B buyback authorization highlight financial strength. 
- **Asia Outperformance**: China/Korea sales +41% YoY, Japan new product driving Banca channel recovery. 
- **VA Runoff Acceleration**: Total VA balances down 50% since 2019, with 2025 target of $24.5B.

**【CEO Opening Remarks】**
- **New Frontier Strategy Execution**: Highlighted the resilience of MetLife's diversified business model amid macroeconomic uncertainty, including higher long-term interest rates and currency volatility. 
- **Q1 Financial Highlights**: Adjusted earnings of $1.3B ($1.96 EPS), up 7% YoY, driven by favorable underwriting margins in Group Benefits and strong RIS inflows. 
- **Risk Transfer Transaction**: Announced $10B reinsurance deal with Talcott Resolution to reduce retail VA tail risk, unlocking $250M in capital value. 
- **Capital Return**: Returned $1.8B to shareholders via dividends and buybacks, with $3B new repurchase authorization. 

**【CFO Financial Details】**
- **Segment Performance**: 
  - **Group Benefits**: $367M adjusted earnings (+29% YoY) from lower mortality in Group Life. 
  - **RIS**: $401M adjusted earnings (+1% YoY) with $1.8B PRT inflows and 8% growth in general account liabilities. 
  - **Asia**: $374M adjusted earnings (-12% YoY) due to FX headwinds, but +10% sales growth in Korea/China. 
- **Expense Efficiency**: Direct expense ratio of 12%, on track for 12.1% full-year target. 
- **Liquidity**: $4.5B cash at holding companies, above $3-4B target buffer. 

**【Key Q&A Takeaways】**
- **Risk Transfer Deal Economics**: $250M capital release vs. $100M annual earnings impact, offset by $45M hedge cost savings. 
- **Asia Growth Momentum**: China/Korea sales up 41% YoY, Japan new USD-denominated product driving Banca channel growth. 
- **VA Runoff Progress**: Total VA balances down 50% since 2019 to $24.5B, with 40% reduction via Talcott transaction. 
- **Capital Strategy**: Prioritize organic growth > M&A > buybacks, with $3B repurchase authorization reflecting Board confidence.

MetLife (MET)-1 May 25-2025 Q1 Earnings call transcript

- **Strategic repositioning success**: Exceeded all 5-year financial targets (ROE 15.2%, $20.7B cash flow) and raised 2025+ growth targets 
- **New Frontier momentum**: 
  - Group benefits PFO growth guidance +100bps to +4-7% 
  - RIS liability growth guidance +100bps to +3-5% 
  - $1.7B VII target for 2025 (vs. $1B in 2024) 
- **Strategic transactions**: $1B+ Chariot Re equity deployment and PineBridge acquisition to accelerate asset management 
- **Resilient cash flow**: $4.7B 2024 buybacks and $25B+ 5-year free cash flow target 
- **Risk management**: 12.1% expense ratio vs. 12.3% target, with 100bps further reduction commitment

**【CEO Opening Remarks】**
- MetLife exceeded all 5-year Next Horizon financial commitments, including ROE of 15.2% (vs. 12-14% target) and $20.7B distributable cash flow (vs. $20B target). 
- Launched New Frontier strategy with 4 priorities: 
  1. Expand group benefits leadership (PFO +8% in 2024) 
  2. Leverage retirement platform ($6.7B PRT inflows in 2024) 
  3. Accelerate asset management growth (PineBridge acquisition pending) 
  4. Expand in high-growth markets (Latin America adj. earnings +21% YoY)
- Announced Chariot Re ($1B+ equity with Chubb) to scale life/retirement solutions and MIM acquisition of Mesirow teams ($6B AUM). 
- 2025+ targets: 
  - Adjusted EPS +10%+ (60% from growth, 40% from capital) 
  - ROE 15-17% 
  - Free cash flow $25B+ over 5 years 
  - Expense ratio -100bps from 12.3% base

**【CFO Financial Review】**
- Q4 2024 adj. EPS: $2.09 (up 14% YoY), driven by: 
  - Group benefits: $416M (down 11% due to non-medical health margins) 
  - RIS: $386M (down 8% due to lower recurring interest) 
  - Asia: $443M (up 50% on VII gains) 
- Full year highlights: 
  - ROE 15.2% (vs. 13-15% guidance) 
  - Direct expense ratio 12.1% (vs. 12.3% target) 
  - Buybacks: $4.7B total ($400M Q4, $470M Jan 2025)
- 2025 outlook: 
  - Group benefits PFO +4-7% (vs. +4-6% prior) 
  - RIS liabilities +3-5% (vs. +2-4% prior) 
  - VII: $1.7B pre-tax (up from $1B in 2024) 
  - FX headwind: $150-175M (yen weakness)

**【Q&A Highlights】**
- **Group benefits competition**: 2025 PFO guidance raised to +4-7% vs. +4-6% prior, driven by product mix shift to higher-margin dental 
- **PRT market resilience**: $6.7B 2024 inflows despite lawsuits; 2025 pipeline remains strong 
- **Investment management growth**: PineBridge acquisition to expand credit capabilities; MIM adj. loss to $850-950M in 2025 
- **Currency risks**: Latin America adj. earnings flat YoY due to MXN/CLP weakness; Asia +mid-single digits on const. curr. 
- **Long-term care trends**: Mortality ratio 84.5% (vs. 84-89% target), with favorable CDC data trends persisting into 2025

Actual																	1.58	0.83	1.73	2.03	2.2	2.37	2.39	2.17	2.08	2	1.21	1.55	1.52	1.94	1.97	1.83	1.83	2.28	1.95	2.09	1.96	2.02	2.34	2.49
Forecast																	1.4369	0.903	1.6116	1.5198	1.5315	1.6842	1.7368	1.4674	1.6499	1.4503	1.1802	1.6666	1.8144	1.9005	1.9441	1.8808	1.8427	2.1035	2.1693	2.1102	2.0027	2.1547	2.321	2.3362
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+9.96%	-8.08%	+7.35%	+33.57%	+43.65%	+40.72%	+37.61%	+47.88%	+26.07%	+37.90%	+2.52%	-7.00%	-16.23%	+2.08%	+1.33%	-2.70%	-0.69%	+8.39%	-10.11%	-0.96%	-2.13%	-6.25%	+0.82%	+6.58%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	15.54B	14.10B	16.02B	19.42B	15.56B	16.24B	16.91B	20.09B	17.72B	18.30B	22.27B	16.32B	15.39B	18.66B	18.24B	19.03B	16.06B	18.75B	18.44B	18.67B	18.57B	17.34B	17.36B	23.81B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	16.38B	15.08B	16.00B	16.21B	16.03B	15.84B	16.28B	17.67B	16.78B	16.04B	20.58B	17.22B	16.84B	16.91B	17.68B	18.46B	17.73B	17.15B	18.66B	19.50B	18.37B	18.53B	18.80B	27.22B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5.14%	-6.49%	+0.09%	+19.76%	-2.93%	+2.49%	+3.83%	+13.70%	+5.64%	+14.09%	+8.20%	-5.22%	-8.62%	+10.32%	+3.15%	+3.10%	-9.43%	+9.36%	-1.16%	-4.30%	+1.07%	-6.45%	-7.67%	-12.52%

MET

MET fundamentals

MET Q4 2025 Earnings

Earnings Call

You can ask Aime

MET

MET fundamentals

MET Q4 2025 Earnings

Earnings Call

MET Earnings Call Summary for Q4/20259:00 AM on Feb 5, 2026

MET Earnings Call Summary for Q3/20259:10 AM on Nov 6, 2025

MET Earnings Call Summary for Q2/20259:00 AM on Aug 7, 2025

MET Earnings Call Summary for Q1/20259:00 AM on May 1, 2025

MET Earnings Call Summary for Q4/20249:00 AM on Feb 6, 2025

You can ask Aime